- Home
- REX vs INBX Comparison
REX vs INBX Comparison
Compare REX & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | INBX |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 1994 | 2024 |
Fundamental Metrics
Financial Performance| Metric | REX | INBX |
|---|---|---|
| Price | $47.10 | $93.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | 196.0K | ★ 331.5K |
| Earning Date | 05-27-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $650,487,000.00 | $1,300,000.00 |
| Revenue This Year | $19.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $83.68 | ★ N/A |
| Revenue Growth | 1.24 | ★ 550.00 |
| 52 Week Low | $30.02 | $20.55 |
| 52 Week High | $64.95 | $155.29 |
Technical Indicators
Market Signals| Indicator | REX | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 58.63 | 44.79 |
| Support Level | $41.97 | $85.94 |
| Resistance Level | $49.21 | $96.12 |
| Average True Range (ATR) | 1.27 | 7.44 |
| MACD | 0.47 | 0.78 |
| Stochastic Oscillator | 81.85 | 33.00 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.